Evogen participates in the global clinical in vitro diagnostic (IVD) market which is valued at approximately $30 billion, of which the fastest growing segments are molecular diagnostics and point of care testing. The IVD market is segmented into the diagnosis and monitoring of specific areas such infectious diseases, critical care, genetics and cancer.
Evogen is developing molecular testing systems to serve the global market with key advantages in affordability, performance and turnaround time enabling everyone to have the genetic testing capability they need.
The Evogen solution is provided through the HyBeacons® probes which can be rapidly developed using proprietary single probes with multiple targets, rather than the more common single probe to single target combination. This allows a more accurate and robust diagnostic assay.
HyBeacon® and HyBeacons® are registered trademarks of LGC Limited, or its affiliate, and of which Evogen is a licensee.